Sol-Gel Technologies Ltd. reports clinical, regulatory and commercial developments for a dermatology business focused on topical drug products for skin diseases. Company updates center on SGT-610, patidegib gel 2%, for the prevention of new basal cell carcinomas in Gorlin syndrome, and SGT-210, erlotinib ointment 5%, which has been evaluated in rare skin keratoderma indications including Darier disease.
News also covers TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea, including product approvals and territorial licensing or commercialization arrangements. Financial releases discuss research and development spending, revenue tied to partnerships and approved products, cash resources, shareholder voting matters, and capital-structure actions such as the company's reverse share split.
Sol-Gel Technologies (NASDAQ: SLGL) announced an anticipated FDA approval of a generic drug in Q2 2021, following a partnership agreement. The brand's sales exceeded $180 million in 2019, indicating significant market potential. This launch could establish a new revenue stream for Sol-Gel in 2021, enhancing its financial outlook. CEO Alon Seri-Levy expressed optimism about the brand's entry into the market, emphasizing its potential benefits for the company's growth.
Sol-Gel Technologies (NASDAQ: SLGL) has expanded its collaboration with Perrigo Company for the development and commercialization of three new generic dermatology product candidates. Perrigo will pursue FDA approval and lead commercialization if successful. This partnership builds on previous agreements and is expected to generate significant revenue for Sol-Gel. Additionally, the company is focused on submitting NDAs for its branded candidates, Epsolay® and Twyneo®, later this year. However, a patent infringement issue has arisen involving Bausch Health regarding a generic version of Bryhali®.
Sol-Gel Technologies (NASDAQ: SLGL) will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 11:00 am Eastern Time. CEO Alon Seri-Levy will speak at the event. Investors can access a live audio webcast on the company's website, with a replay available for 30 days. Sol-Gel focuses on developing topical drug products for skin diseases, leveraging its microencapsulation technology. The company's pipeline includes treatments for acne and rosacea, along with other early-stage and preclinical assets.
Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will feature CEO Dr. Alon Seri-Levy, CFO Gilad Mamlok, and U.S. Head of Commercialization John Vieira on June 2, 2020, at 11:00 am ET. Additionally, the Raymond James Human Health Innovation Conference will take place on June 18, 2020, with Dr. Seri-Levy speaking at 11:40 am ET. Live webcasts will be available on Sol-Gel's website, which will also host archived recordings for around 30 days post-event.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will release its first quarter 2020 financial results and operational highlights on May 14, 2020, at 7:05 AM ET. The company specializes in developing branded and generic topical drugs for skin diseases, utilizing proprietary microencapsulation technology for products such as Twyneo for acne and Epsolay for rosacea. Sol-Gel's pipeline includes early-stage treatments like SGT-210 for keratoderma and preclinical assets tapinarof and roflumilast.